Iloperidone

'iloperidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults. it belongs to the chemical class of piperidinyl-benzisoxazole derivatives. Its chemical name is 4''-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3''-methoxyacetophenone. Its molecular formula is C24H27FN2O4 and its molecular weight is 426.48. The structural formula is: iloperidone Structural Formula Illustration'

Brands
ILODON ILODON ILODON ILODON
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to piperidinyl-benzisoxazole derivatives.. It belongs to Antipsycatic pharmacological group.The Molecular Weight of iloperidone is 426.48.
Contraindications
iloperidone
Effects
The symptomatic adverse reactions produced by iloperidone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fatigue, Tachycardia, Dry mouth, Weight gain, Somnolence, Nasal congestion, Orthostatic hypotension, Dry mouth, dizziness, Tachycardia.
Indications
iloperidone is primarily indicated in conditions like Schizophrenia.
Interactions
No data regarding the interactions of iloperidone was found.
Interfrence
Fasting blood glucose testingchange in Cholestrol levelchange in triglycerideschange in lipids
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
tablet Store at room temperature, Between 15°C-30°C. Refrigeration and Freezing is not recommended. Protect from Sunlight, Moisture and Heat.
Warnings
eldery patient with demntia related phychosis are not approved to treat with iloperidone Abrupt discontinuation is not advised €¢ Cognitive and motor impairment risk €¢ Concomitant use with drugs that prolong the QT interval should be avoided €¢ Diabetes mellitus or risk factors for diabetes mellitus; increased risk of severe hyperglycemia €¢ Dysphagia risk (risk of aspiration) €¢ Exposure to extreme temperatures (hypothermia) €¢ Elderly patients, particularly elderly women, are at increased risk of tardive dyskinesia €¢ Hematological disease (neutropenia, agranulocytosis, etc) €¢ Hepatic disease €¢ Hypotensive medication use, low BP €¢ Increased duration of therapy and/or higher cumulative doses €¢ Seizure disorder, history, or conditions which lower seizure threshold €¢ Substance abuse history €¢ Risk of suicide €¢ Tardive dyskinesia, potentially irreversible
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.